|Systematic (IUPAC) name|
|Mol. mass||140.14 g/mol|
| (what is this?)
Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck. In March, 2007, Merck and H. Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a very different way from benzodiazepines and Z-drugs (zolpidem, zaleplon, etc.). Lundbeck states that gaboxadol also increases deep sleep (stage 4). Unlike benzodiazepines, it is not reinforcing.
See also 
- US Patent 4278676 - Heterocyclic compounds
- 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol at the US National Library of Medicine Medical Subject Headings (MeSH)
- H. Lundbeck Website
- Medical News Today article
- Report of cancellation of development.
|This sedative-related article is a stub. You can help Wikipedia by expanding it.|